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ABSTRACT Previously we found that interleukin 2 (IL-2)
induces tyrosine phosphorylation and activation of the ser-
ine/threonine-specific kinase encoded by the raf-l protoonco-
gene in a T-cell line, CTLL-2. Here we extended these rmdings
by exploring the effects of selective removal of phosphate from
tyrosines in p72-74-Raf-i kinase that had been immunopre-
cipitated from IL-2-stimulated CTLL-2 cells. Treatment in
vito of IL-2-activated Raf-i with the tyrosine-specific phos-
phatases CD45 and TCPTP (formerly called T-cell protein
tyrosine phosphatase) reduced Raf kinase activity to nearly
baseline levels. This effect was completely inhibited by the
phosphatase inhibitor sodium orthovanadate. In contrast,
treatment of Raf-i with a serine/threonine-specific phospha-
tase, protein phosphatase 1 (PP-1), resulted in a more modest
decrease in Raf in vitro kinase activity, and this effect was
prevented by okadaic acid. Two-dimensional phosphoamino
acid analysis confirmed the selective removal of phosphate
from tyrosine by CD45 and from serine and threonine by PP-1.
The immunoreactivity of p72-74-Raf-i with anti-phosphoty-
rosine antibodies was also completely abolished by treatment
with CD45 in the absence but not in the presence of sodium
orthovanadate. These findings provide evidence that the IL-
2-stimulated phosphorylation of Raf-i on tyrosines plays an
important role in upregulating the activity of this ser-
ine/threonine-specific kinase in CTLL-2 cells and, as such,
provides a model system for studying the transfer of growth
factor-initiated signals from protein tyrosine kinases to ser-
ine/threonine-specific kinases.
Interleukin 2 (IL-2) regulates the growth, survival, and cy-
tolytic killing activity of T lymphocytes (1). Although this
lymphokine has shown some efficacy in enhancing immune
responses to tumors in patients, the severe side effects of
systemic IL-2 administration have drastically limited its
clinical uses (2). An improved knowledge of the molecular
events that occur in T cells upon binding of IL-2 thus could
potentially contribute to more effective manipulation of im-
mune-cell responses against cancer.
CTLL-2 was originally described as a tumor-specific cy-
tolytic T cell that was isolated from mice and that could be
maintained long-term in culture with IL-2 (3). This T-cell line
has been used extensively as a model for investigations ofthe
mechanisms of IL-2 signal transduction. Unlike many other
growth factor receptors (4), the known subunits of the IL-2
receptor complex lack homology with protein-tyrosine ki-
nases (PTKs) (5-7). Nevertheless, tyrosine phosphorylation
of numerous intracellular proteins occurs rapidly in CTLL-2
and other T cells when stimulated with IL-2 (8-10), and
pharmacological inhibitors of PTKs prevent most of the
biochemical and cellular events that normally follow from
exposure ofT cells to IL-2 (see refs. 11 and 12 for examples).
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Ultimately, however, it is believed that growth factor-
activated PTKs pass their information on to serine/
threonine-specific kinases in a signal transduction cascade
that eventually reaches the nucleus, resulting in the changes
in gene expression that lead to cellular proliferation, sup-
pression of apoptosis, and other responses.
The 72- to 74-kDa kinase encoded by the raf-J protoonco-
gene is a good candidate for a serine/threonine-specific
kinase that receives its activation signals directly from up-
stream PTKs. Although somewhat controversial, Raf-1 was
originally reported to become phosphorylated on tyrosines in
platelet-derived growth factor-stimulated fibroblasts and was
shown to physically associate with platelet-derived growth
factor receptors (13). Subsequently, the lymphokines IL-2,
IL-3, and granulocyte-macrophage colony-stimulating factor
were found to induce tyrosine phosphorylation and activation
of Raf-1 in hematolymphoid cells (14-16). The tyrosine
phosphorylation of Raf-1 occurs with high stoichiometry in
some lymphokine-dependent cells, including IL-2-stimulated
CTLL-2 cells where 20-50% of the total incorporated 32P04
was found on tyrosines (14). Furthermore, a physical asso-
ciation between Raf-1 and the p75 13 chain ofthe IL-2 receptor
has been described (17), suggesting that it may be a proximal
player in an IL-2-regulated signal transduction cascade. An
important gap in these scenarios that have placed Raf-1 in a
likely position to relay information from PTKs to down-
stream serine/threonine-specific kinases concerns the func-
tional significance of the tyrosine phosphorylation that has
been observed in Raf-1 after stimulation of cells with lym-
phokines and other types ofgrowth factors. Here we describe
the results of experiments in which tyrosine-specific protein
phosphatases were used to remove phosphates selectively
from tyrosine residues in Raf-1 and the effects on Raf-1 in
vitro kinase activity were then determined.
MATERIALS AND METHODS
Cell Cultures. CTLL-2 cells were adapted to growth in
RPMI 1640 medium containing 1 mM L-glutamine, 10%
(vol/vol) heat-inactivated fetal bovine serum, and 10% (vol/
vol) conditioned medium from the IL-2-producing cell line
MLA-144 (18) and were then maintained in this medium as
described (14). All experiments were performed 3 days after
plating CTLL-2 cells, when the cells had reached their
plateau phase of growth and had consumed most of the IL-2
in the cultures. Cells were washed three times with RPMI
1640 medium to remove residual lymphokine and then re-
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turned to culture for 7-10 h in medium lacking IL-2. In some
cases, the cells were resuspended in phosphate-free medium
and 32P04 (0.2 mCi/ml; 1 Ci = 37 GBq) was added to the
cultures during this 7- to 10-h period to metabolically label the
cells. Quiescent CTLL-2 cells were then restimulated with
100 units of recombinant human IL-2 per ml (generous gift
from Cetus/Chiron) (19) for 5 min.
Antibodies, Immunoprecipitations, and Immunoblotting.
The Raf-l-specific monoclonal antibody URP3OS3 was used
for most experiments (20). In some cases, rabbit antisera
generated against the SP63 peptide corresponding to the C
terminus of Raf kinases were used (21). The anti-
phosphotyrosine monoclonal antibody 4G10 was purchased
from Upstate Biotechnology (Lake Placid, NY). Immuno-
precipitations and immunoblot analysis of Raf-1 were per-
formed exactly as described except that 4G10 was used at a
dilution of 1:50,000 (vol/vol) and an emission chemilumines-
cence detection system was used (Amersham). Exposure
times with Kodak XRP film were typically 15-30 s.
Phosphatase Treatments and in Vitro Raf Kinase Assays.
Raf-l-containing immunoprecipitates were prepared from
either unlabeled or 32P04-labeled CTLL-2 cells and treated
for 30-60 min at 30°C with either 100 units of CD45 per ml,
100 units ofTCPTP (T-cell protein tyrosine phosphatase) per
ml, or 76 units of protein phosphatase 1 (PP-1) per ml in 50
p1 of a solution containing 25 mM Hepes (pH 7.2), 2 mM
dithiothreitol, 5 mM EDTA, 0.05% Triton X-100, 5% (vol/
vol) glycerol, 5% 2-mercaptoethanol, and 1 mg of bovine
serum albumin per ml (22-24). For some samples, either 1
mM sodium orthovanadate or 1 ,uM okadaic acid was added
before the phosphatases, but all reactions were stopped by
addition of these phosphate inhibitors. For 32P04-labeled
Raf-1, the immunoprecipitates were washed five times in
modified RIPA lysis buffer (14) before analysis by SDS/
PAGE using 7.5% gels. In some cases, the bands correspond-
ing to 32P04-labeled Raf-1 were excised from gels, acid
hydrolyzed, and analyzed by two-dimensional electrophore-
sis with 0.1-mm plastic-backed thin-layer cellulose plates
(EM Science) as described (14). For unlabeled Raf-1, immu-
noprecipitates were washed twice with a buffer containing
1% Triton X-100 (14), once with 0.5 M LiC12/50 mM
Tris HCl, pH 7.4, and once with water before in vitro kinase
assays using a synthetic peptide as substrate exactly as
described (14, 25, 26).
RESULTS
To determine the functional significance of tyrosine phos-
phorylation in regulation of Raf-1 kinase activity in IL-2-
stimulated CTLL-2 cells, we used purified tyrosine-specific
phosphatases CD45 and TCP to specifically dephosphorylate
tyrosines in p72-74-Raf-1 and then determined the effect of
Table 1. Effect of phosphatase treatments on in vitro kinase activity of Raf-1
Phosphatase
Stimulation Phosphatase inhibitor Raf kinase activity
with IL-2 CD45 TCP PPI Na3VO4 Oka Total cpm Corr cpm Rel. activity
Experiment 1
- - - - -
- 4,380 1124 1.0
+ - - - - - 7,694 4494 3.8
+ + - - - - 4,820 1620 1.3
+ + - - + - 10,024 6824 5.7
+ - + - - - 3,692 492 1.0
+ - + - + - 8,094 4894 4.4
+ - - + - - 6,100 2900 2.5
+ - - + - + 6,864 3664 3.1
Experiment 2
- - - - - - 2,016 1612 1.0
+ - - - - - 6,760 6356 4.0
+ + - - - - 2,656 2252 1.4
+ + - - + - 6,736 6332 3.9
+ - + - - - 2,716 2312 1.4
+ - + - + - 5,936 5532 3.4
+ - - + - - 5,044 4640 2.9
+ - - + - + 5,476 5072 3.1
Experiment 3
- - - - - - 673 1.0
+
_ _
- -
- 2,903 - 4.3
+ + - - - - 998 - 1.5
+ + - - + - 2,820 - 4.2
+ - + - - - 902 - 1.3
+ - + - + - 2,571 - 3.8
+ - - + - - 2,452 3.6
+
_
- + - + 2,963 4.4
CTLL-2 cells were deprived of IL-2 for 7-10 h and then restimulated for 5 min with 100 units of recombinant human IL-2
per ml (+) or left unstimulated (-) before immunoprecipitating Raf-1 with the URP3OS3 monoclonal antibody. Immune
complexes were then treated with various phosphatases in the presence or absence of the phosphatase inhibitor NaVO4 or
okadaic acid (Oka) (22-24). After stopping reactions by addition of phosphatase inhibitors to all samples, followed by
washing, the immune complexes from duplicate samples were resuspended in kinase reaction buffer containing 20mM NaF
and 1 mM NaVO4, [hy.32P]ATP, and either a synthetic peptide substrate, IVQQFGFQRRASDDGKLTD, or a peptide lacking
a serine phosphate acceptor site, IVQQFGFQRRAADDGKLTD, essentially as described (14, 25, 26). Total of 32p
incorporation into the substrate peptide was corrected for background by subtracting the cpm obtained when the
serine-deficient peptide was used (Corr cpm). Relative kinase activity (Rel activity) was calculated by normalizing all data
relative to the corrected cpm value obtained with IL-2-deprived CTLL-2 cells, which was set at 1.0. Data from three
experiments are presented.
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this treatment on the activity of this kinase in vitro. Table 1
summarizes the results of three experiments. As shown,
stimulation ofCTLL-2 cells for 5 min with IL-2 resulted in an
-4-fold increase in Raf-1 kinase activity, as measured by an
in vitro kinase assay that uses a synthetic peptide as the
substrate (14, 25, 26). Treatment ofRaf-1 immunoprecipitates
with CD45 or TCPTP markedly reduced Raf-1 kinase activ-
ity, bringing it down to levels approaching the baseline
activity seen in unstimulated CTLL-2 cells. When the tyro-
sine phosphatase inhibitor sodium orthovanadate was in-
cluded in the phosphatase reactions, no loss of Raf-1 kinase
activity occurred, thus demonstrating the specificity of this
effect. Heat denaturing the phosphatase before use also
abolished inhibitory activity (data not shown). Treatment of
Raf-1 immunoprecipitates with the serine/threonine-specific
phosphate PP-1 also reduced Raf-1 kinase activity in vitro,
but to a lesser extent than the tyrosine-specific phosphatases
(Table 1). When the phosphatase inhibitor okadaic acid was
included in the reactions with PP-1, little or no reduction in
Raf-1 kinase activity was observed.
As a first attempt to confirm that the CD45 and TCPTP
phosphatases were effectively dephosphorylating tyrosinyl
residues in Raf-1, we subjected Raf-1 immunoprecipitates to
immunoblot analysis using the anti-phosphotyrosine-specific
antibody 4G10. As shown in Fig. 1, Raf-1 immunoprecipi-
tated from unstimulated CTLL-2 cells contained little or no
detectable phosphotyrosine, at least as defined by this assay.
Stimulation of CTLL-2 cells for 5 min produced a large
increase in the immunoreactivity of Raf-1 with the 4G10
antibody, consistent with the ability of IL-2 to stimulate
tyrosine phosphorylation of Raf-1 in these T cells. Increases
in the binding of4G10 to both the 72- and 74-kDa Raf-1 bands
were observed. The slower-migrating form of Raf-1 with an
apparent molecular mass of 74 kDa has been attributed to a
phosphorylation-induced conformational change in the ki-
nase (25). Raf-1 that had been recovered from IL-2-
stimulated CTLL-2 cells and treated with CD45 or TCPTP
exhibited little or no immunoreactivity with the phosphoty-
rosine-specific antibody (Fig. 1; data not shown), suggesting
effective dephosphorylation oftyrosinyl residues in Raf-1. As
expected, when sodium orthovanadate was included in the
phosphatase reactions, essentially no reduction in the binding
of 4G10 to Raf-1 was observed. As a control, Raf-1 immu-
noprecipitates were also treated with the PP-1, which pro-
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FIG. 2. Effect of PP-1 on 32PO4 content of p72-74-Raf-1. CTLL-2
cells were metabolically labeled with 32PO4 and Raf-1 was immuno-
precipitated from these IL-2-deprived cells before (lane C) or after
restimulation with recombinant IL-2 (rIL2). Immune complexes
were then treated with PP-1 in the presence or absence of okadaic
acid as indicated. The resulting proteins were analyzed by SDS/
PAGE (7.5% gels) and autoradiography.
duced little or no change in the immunoreactivity of Raf-1
with the 4G10 antibody.
As an initial attempt to confirm that the serine/threonine-
specific phosphatase PP-1 was dephosphorylating Raf-1,
CTLL-2 cells were metabolically labeled with 32P04. Raf-1
was then immunoprecipitated from the cells and treated with
PP-1 in the presence or absence of okadaic acid. As shown in
Fig. 2, IL-2 induced a marked increase in the phosphorylation
of p72-Raf-1 and led to the appearance of the slower-
migrating form of Raf-1, consistent with previous reports (14,
27). Treatment of the immunoprecipitated 32P04-labeled
Raf-1 with PP-1 resulted in a large decrease in the radioactive
signal, suggesting removal of the majority of 32pO4 from the
kinase. Inclusion of the phosphatase inhibitor okadaic acid in
the reaction mixtures abrogated most of this effect of PP-1.
Finally, to biochemically confirm the selectivity of the
various phosphatases for dephosphorylation of the expected
amino acids, Raf-1 was immunoprecipitated from 32P04-
labeled CTLL-2 cells after IL-2 restimulation and treated
with either CD45 or PP-1. The resulting Raf-1 proteins were
then acid hydrolyzed and the products were compared side-
by-side in the same two-dimensional plate, each sample thus
serving as a control for the other. As shown in Fig. 3,
CD45-treated Raf-1 kinase contained phosphoserine and
phosphothreonine but very little phosphotyrosine. Con-
versely, PP-1-treated Raf-1 contained predominantly phos-
photyrosine, but only scant amounts of phosphothreonine,
+IL2
+PP1
_ ~ s
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FIG. 1. Analysis of phosphatase-treated p72-74-Raf-1 by immu-
noblot assay using an anti-phosphotyrosine-specific antibody. Raf-1
was immunoprecipitated from IL-2-deprived CTLL-2 cells (lane C)
and from CTLL-2 cells that had been restimulated for 5 min with
recombinant IL-2 (rIL2). The resulting immune complexes were then
treated with either CD45 or PP-1 in the presence or the absence of
sodium orthovanadate as indicated. Raf-1-containing immunopre-
cipitates were then subjected to SDS/PAGE and transferred to
nitrocellulose filters for incubation with 4G10 antibody. Blots were
then washed, and the bound 4G10 monoclonal antibody was detected
by incubation with a horseradish-peroxidase-conjugated antibody
and the chemiluminescent substrate luciferase. Exposure to x-ray
film was for 30 s. Data are representative of several experiments.
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FIG. 3. Phosphoamino acid analysis of p72-74-Raf-1 after treat-
ment with CD45 or PP-1. Raf-1 kinase was immunoprecipitated from
IL-2-stimulated CTLL-2 cells that had been metabolically labeled
with 32PO4 and treated for 60 min with either PP-1 or CD45. After
subjecting the immune complexes to SDS/PAGE, the p72 and p74
Raf-1 bands were excised from the gels and acid hydrolyzed, and the
resulting phosphoamino acids were separated by two-dimensional
electrophoresis using thin-layer cellulose plates. Electrophoresis in
pH 3.5 buffer was at 1 kV for 55 min, whereas the pH 1.9 dimension
was run at 1 kV for 45 min. As standards, unlabeled phosphotyrosine
(PY), phosphoserine (PS), and phosphothreonine (PT) were mixed
with the samples and their relative positions were revealed by
treatment ofthe plates with ninhydrin vapor. Only selected standards
are outlined in the figure.
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and markedly reduced levels ofphosphoserine. The results of
this phosphoamino acid analysis thus confirm the specificity
of the CD45 and PP-1 phosphatases for selective dephos-
phorylation of tyrosines and serines/threonines, respec-
tively, in Raf-1 under the conditions used here.
DISCUSSION
Previously, we reported that IL-2 induces phosphorylation
and activation of the p72-74-Raf-1 kinase in CTLL-2 cells
(14). The extent of IL-2-induced phosphorylation on tyrosine
varied from 20% to 50o of the total 32P04 incorporated into
Raf-1. The relatively high stoichiometry of tyrosine phos-
phorylation in these T cells thus created an opportunity to
assess the functional significance of this posttranslational
modification in the regulation of Raf-1 kinase activity. When
treated with CD45 or TCPTP, levels of Raf-1 kinase activity
in vitro were reduced by an average of 68% (Table 1). This
result is in reasonable agreement with our previous finding
that about one-half of the immunodetectable Raf-1 protein in
IL-2-stimulated CTLL-2 cells can be immunoprecipitated
with anti-phosphotyrosine antibodies (14). This large dimi-
nution in Raf-1 kinase activity that occurred upon dephos-
phorylation of tyrosine strongly suggests that IL-2-induced
tyrosine phosphorylation of Raf-1 plays a major role in
activation of this serine/threonine-specific kinase in CTLL-2
cells. Studies to map and mutate the sites of tyrosine phos-
phorylation in Raf-1 in order to confirm this hypothesis
remain to be done.
Although tyrosine phosphorylation appears to represent a
mechanism for activating the Raf-1 kinase in IL-2-stimulated
CTLL-2 cells, this kinase can also be activated by pathways
involving exclusively serine and threonine phosphorylation.
Phorbol esters that activate protein kinase C, for example,
are potent inducers of Raf-1 kinase phosphorylation and
activation (25, 27, 28). In this regard, Siegel et al. (29)
reported that antibodies directed against the T-cell antigen
receptor complex stimulated phosphorylation and activation
of Raf-1 in a T-cell hybridoma through a protein kinase
C-dependent mechanism that involved no detectable tyrosine
phosphorylation. Similarly, phosphorylation of Raf-1 in fi-
broblasts stimulated with epidermal growth factor or insulin
and in hematopoietic cells stimulated with colony-stimulating
factor 1 appears to occur exclusively on serines and thre-
onines (26, 30, 31). In some but not all fibroblasts, platelet-
derived growth factor may be able to stimulate tyrosine
phosphorylation of Raf-1 but this occurs at very low stoichi-
ometry relative to serine/threonine phosphorylation (13, 29,
31), suggesting that the latter represents a more quantitatively
important mechanism for activating Raf-1 in those cells.
Similarly, although IL-3 and granulocyte-macrophage colo-
ny-stimulating factor are able to stimulate tyrosine phosphor-
ylation of Raf-1 with relatively high stoichiometry in some
myeloid cell lines (15), tyrosine phosphorylation occurs with
much lower stoichiometry in others (16), again suggesting
that serine/threonine phosphorylation may be a more com-
mon mechanism for achieving activation of Raf-1.
Somewhat surprising, therefore, was the less striking effect
that the serine/threonine-specific phosphatase PP-1 had on
Raf-1 kinase activity in vitro in our experiments (Table 1).
This observation raises the possibility that serine/threonine
phosphorylation events are relatively less important for reg-
ulating the activity of Raf-1 in IL-2-stimulated CTLL-2 cells.
It should be noted, however, that PP-1 removed only -70%
ofphosphoserine from Raf-1, whereas CD45 produced nearly
complete dephosphorylation of tyrosine (Fig. 3). Thus, the
importance of serine phosphorylation in activating the Raf-1
kinase in IL-2-stimulated CTLL-2 cells could have been
underestimated. Furihermore, we cannot from these exper-
iments determine whether tyrosine phosphorylation can by
itself activate the Raf-1 kinase independent of serine/
threonine phosphorylation.
Because CTLL-2 cells differ from normal T cells in their
ability to remain constantly responsive to IL-2 in the absence
ofperiodic stimulation with antigen, the high stoichiometry of
tyrosine phosphorylation of Raf-1 observed in these cells may
represent a special circumstance. Regardless of how accu-
rately the events described here in CTLL-2 cells quantita-
tively and qualitatively reflect the situation in normal T cells,
these IL-2-dependent T cells provide a model system for
molecular explorations of the mechanisms by which the
activity of the serine/threonine-specific Raf-1 kinase can be
regulated by tyrosine phosphorylation.
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